Marcus Trybula
Hematology & Oncology · Lebanon, OHNPI 1487114989
Payments from drug & device makers
Across 115 payments — averaging $26.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Seagen Inc.$353
- Incyte Corporation$265
- Merck$232
- AstraZeneca$217
- Novartis$196
- Astellas Pharma US Inc$188
- plus $2K from 28 others
What the payments were for
- Food & beverage$2,34578%
- Education$65622%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Seagen Inc. | 6 | $353 |
| Incyte Corporation | 9 | $265 |
| Merck | 10 | $232 |
| AstraZeneca(2 entities) | 10 | $217 |
| Novartis | 10 | $196 |
| Astellas Pharma US Inc | 4 | $188 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $182 |
| Pfizer | 8 | $162 |
| Bristol Myers Squibb | 6 | $113 |
| Daiichi Sankyo Inc. | 4 | $102 |
| Sanofi | 5 | $94 |
| Blueprint Medicines Corporation | 3 | $93 |
| Beone Medicines USA, Inc. | 3 | $86 |
| Sanofi-aventis U.S. LLC | 1 | $82 |
| Eisai Inc. | 4 | $79 |
| Amgen | 3 | $67 |
| AbbVie | 2 | $53 |
| Sobi, Inc | 2 | $42 |
| Gilead | 2 | $41 |
| Jazz Pharmaceuticals Inc. | 2 | $39 |
| Rigel Pharmaceuticals, Inc. | 2 | $39 |
| Array Biopharma Inc | 2 | $33 |
| Lilly USA, LLC | 1 | $27 |
| Agios Pharmaceuticals, Inc. | 1 | $25 |
| AVEO Pharmaceuticals, Inc. | 1 | $23 |
| Stemline Therapeutics Inc. | 1 | $23 |
| Genentech USA, Inc. | 1 | $23 |
| E.r. Squibb & Sons, L.L.C. | 1 | $21 |
| Bayer | 1 | $19 |
| Beigene USA, Inc. | 1 | $18 |
| Genmab U.S., Inc. | 1 | $18 |
| Johnson & Johnson | 1 | $18 |
| Springworks Therapeutics, Inc. | 1 | $14 |
| Novocure Inc. | 1 | $14 |
How this compares
$3,001 in reported general payments places this provider in the 40th percentile of 450 hematology & oncology providers in Ohio.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 19 | $263,498 |
| Posaconazole | 12 | $23,007 |
| Anastrozole | 36 | $383 |
| Levofloxacin | 11 | $101 |
| Potassium Chloride | 11 | $71 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi | $188 | $263,49819 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 450 hematology & oncology providers in Ohio.
Other hematology & oncology in Lebanon
- Afshin DowlatiCleveland$25.1M
- Brian HillCleveland$11.6M
- Trisha Wise-DraperCincinnati$9.8M
- Davendra SohalCincinnati$8.6M
- Christopher HoimesCleveland$7.5M
- Balazs HalmosCleveland$7M
- David WaterhouseCincinnati$5.7M
- Dale ShepardCleveland$5.1M
- Paolo CaimiCleveland$4.2M
- Allison WinterCleveland$4.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.